Crouse Health Online: Wellness is just a click away.
Share Share
  |  Connect with Us: 
large
med
small
Text Size
 

Health News



First Drug Ok'd to Combat Spreading Basal Cell Skin Cancer

First Drug Ok'd to Combat Spreading Basal Cell Skin Cancer

01/30/12

MONDAY, Jan. 30 (HealthDay News) -- The U.S. Food and Drug Administration on Monday approved a drug to treat the most common form of skin cancer, basal cell carcinoma.

Erivedge (vismodegib) is the first drug sanctioned in the United States to treat basal cell skin cancer that has metastasized, or spread. The once-daily pill is also designed for cases deemed unsuitable for surgery or radiation, the agency said in a news release.

This usually slow-growing, painless form of cancer starts in the epidermis, the top layer of skin. Frequent exposure to sunlight and other forms of ultraviolet radiation are the typical causes, the FDA said.

Researchers evaluated the safety and effectiveness of Erivedge in a clinical study of 96 people with locally advanced or metastatic cancer. Of those with metastatic disease, 30 percent had at least a partial response to the drug, while 43 percent of people with locally advanced basal cell had at least a partial response.

One specialist welcomed the drug's approval.

"Eviredge is an amazing revolutionary approach to treating skin cancer," said Dr. Michele Green, dermatologist at Lenox Hill Hospital in New York City. "I have many patients who are elderly and infirm for whom getting surgery is a major ordeal. Molecular biology has advanced to the point where such an important advance in therapy was unthinkable even a few years ago."

Skin cancer is the most commonly diagnosed cancer in the United States, and it is estimated that one in five Americans will develop it in their lifetime. Caught early, it is highly treatable.

The most frequently cited side effects of Erivedge included muscle spasms, hair loss, weight loss, nausea, diarrhea, fatigue, distorted sense of taste, decreased appetite, constipation and vomiting.

Because of the potential risk for death or severe birth defects to a fetus, the drug will be packaged with a label warning, and doctors will not prescribe it to women who are pregnant, the agency said. Men and women will be advised to use birth control while taking the pills.

Erivedge, marketed by San Francisco-based Genentech, won expedited approval under a priority review program for drugs that may represent a major treatment advance.

More information

The Skin Cancer Foundation has details about basal cell.

Copyright © 2012 HealthDay. All rights reserved.

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.

OF INTEREST:
 

Latest News

Crouse Hospital Appoints Chief Information Officer
more >

MedEx Bedside Prescription Delivery Service

Free service offers convenience, patient education at discharge.
more >

Weight Loss Surgery

Is it right for you? Attend a free information seminar held twice monthly.
more >

Quality at Crouse

See how Crouse Hospital strives to provide the best in patient care.
more >

Cheer Up That Special Someone

Say get well or welcome a new arrival with a gift purchased right at Crouse.

more >

Make an Online Donation Now

Your donation of any amount helps support Crouse services & programs in a meaningful way.
more >

Shop Online Now

Say get well, thinking of you or welcome new baby with a unique gift from the Crouse Gift Shop.

more >